Mortality in people with psychotic disorders in Finland: a population-based 13-year follow-up study

Simple item page
dc.contributor.authorKeinänen, Jaakko
dc.contributor.authorMantere, Outi
dc.contributor.authorMarkkula, Niina
dc.contributor.authorPartti, Krista
dc.contributor.authorPerälä, Jonna
dc.contributor.authorSaarni, Samuli I.
dc.contributor.authorHärkänen, Tommi
dc.contributor.authorSuvisaari, Jaana
dc.date.accessioned2017-08-28T19:36:26Z
dc.date.available2017-08-28T19:36:26Z
dc.date.issued2017
dc.description.abstractOBJECTIVES: We conducted a population based study aiming at finding predictors of mortality in psychotic disorders and evaluating the extent to which sociodemographic, lifestyle and health-related factors explain the excess mortality. METHODS: In a nationally representative sample of Finns aged 30-70years (n=5642), psychotic disorders were diagnosed using structured interviews and medical records in 2000-2001. Information on mortality and causes of death was obtained of those who died by the end of year 2013. Cox proportional hazards models were used to investigate the mortality risk. RESULTS: No people with affective psychoses (n=36) died during the follow-up, thus the analysis was restricted to non-affective psychotic disorders (NAP) (n=106). Adjusting for age and sex, NAP was statistically significantly associated with all-cause mortality (hazard ratio (HR) 2.99, 95% CI 2.03-4.41) and natural-cause mortality (HR 2.81, 95% CI 1.85-4.28). After adjusting for sociodemographic factors, health status, inflammation and smoking, the HR dropped to 2.11 (95% CI 1.10-4.05) for all-cause and to 1.98 (95% CI 0.94-4.16) for natural-cause mortality. Within the NAP group, antipsychotic use at baseline was associated with reduced HR for natural-cause mortality (HR 0.25, 95% CI 0.07-0.96), and smoking with increased HR (HR 3.54, 95% CI 1.07-11.69). CONCLUSIONS: The elevated mortality risk in people with NAP is only partly explained by socioeconomic factors, lifestyle, cardio-metabolic comorbidities and inflammation. Smoking cessation should be prioritized in treatment of psychotic disorders. More research is needed on the quality of treatment of somatic diseases in people with psychotic disorders.
dc.format.extent1
dc.identifier.citationSchizophr Res. 2017 May 9. pii: S0920-9964(17)30257-8
dc.identifier.urihttp://hdl.handle.net/11447/1612
dc.identifier.urihttp://dx.doi.org/10.1016/j.schres.2017.04.048
dc.language.isoen_US
dc.publisherElsevier
dc.subjectComorbidity
dc.subjectMortality
dc.subjectPsychotic disorders
dc.subjectSomatic disease
dc.titleMortality in people with psychotic disorders in Finland: a population-based 13-year follow-up study
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mortality in people with psychotic disorders in Finland A population-based 13-year follow-up study__2.pdf
Size:
181.52 KB
Format:
Adobe Portable Document Format
Description:
Resumen
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services